dailynews.ascopubs.org/do/cdk4-6-in...
dailynews.ascopubs.org
CDK4/6 Inhibitor Rechallenge in ER-Positive Breast Cancer: Understanding Which Patient Populations May Benefit
Rechallenge with CDK4/6 inhibitors may be beneficial in select patients; incorporating disease-free interval, molecular profiling, and previous treatment response can help guide rechallenge decisions....
